Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Replagal in Children with Fabry Disease
NCT00084084Phase 2Completed
- Sponsor
- Takeda
- Start
- Jun 2004
- Primary completion
- Jun 2011
- Modality
- Replacement Enzymes
- Countries
- 2
01
Overview
Phase 2, open-label trial of agalsidase alfa in Fabry disease (FD) (2 cohorts), sponsored by Takeda. Primary endpoints: Patients Who Experienced At Least One Adverse Event at 362 weeks and Heart Rate Variability - Change From Baseline in SDNN at Week 185. Started Jun 2004; status: completed.
02
Drugs
agalsidase alfa
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT00084084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00084084.